Previous 10 | Next 10 |
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed ...
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp (TDUP) +7%. Cellectis (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats (SEAT) -6%. Y-mAbs Therapeutic...
Spruce Biosciences press release (NASDAQ:SPRB): FY GAAP EPS of -$1.81. FY net loss $42.3M For further details see: Spruce Biosciences GAAP EPS of -$1.81
Spruce Biosciences (NASDAQ:SPRB) has appointed Will Charlton, a board-certified pediatric endocrinologist with over 15 years of clinical research experience, as its new Chief Medical Officer. Dr. Charlton will succeed Rosh Dias, who has stepped down to pursue other opportunities. Prior to thi...
Topline Safety Data from Cohort 1 of Phase 2 Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton, M.D., M.A.S., Appointed Chief Medical Officer Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and co...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, M.D., M.A.S., has been appointed Chief Med...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming inves...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, an...
Topline Data from CAHmelia-203 and CAHmelia-204 Anticipated in 2H 2023 and 2H 2024, Respectively Strategic Reprioritization Extends Anticipated Cash Runway by 6 Months into Q2 2024 CAHmelia Program in Adult Classic CAH to Significantly Expand Sites Globally, Planned In...
– Samir Gharib, MBA, Promoted to President – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today an...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...